Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.28 and traded as high as $4.92. Cumberland Pharmaceuticals shares last traded at $4.65, with a volume of 208,690 shares traded.

Analyst Ratings Changes

Several brokerages have weighed in on CPIX. Wall Street Zen raised Cumberland Pharmaceuticals to a “hold” rating in a report on Saturday, January 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Stock Performance

The firm’s 50 day simple moving average is $3.29 and its 200 day simple moving average is $3.28. The firm has a market capitalization of $69.56 million, a price-to-earnings ratio of -19.38 and a beta of -0.53. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.11 and a current ratio of 1.23.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter. The business had revenue of $8.29 million during the quarter. Cumberland Pharmaceuticals had a positive return on equity of 5.13% and a negative net margin of 8.06%.

Institutional Trading of Cumberland Pharmaceuticals

A number of hedge funds have recently modified their holdings of CPIX. Heron Bay Capital Management acquired a new stake in Cumberland Pharmaceuticals during the second quarter worth about $111,000. XTX Topco Ltd purchased a new stake in Cumberland Pharmaceuticals in the 2nd quarter worth approximately $34,000. Bridgeway Capital Management LLC grew its stake in shares of Cumberland Pharmaceuticals by 2.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after purchasing an additional 4,200 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Cumberland Pharmaceuticals by 11.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after purchasing an additional 27,980 shares during the period. Finally, Two Sigma Investments LP increased its holdings in shares of Cumberland Pharmaceuticals by 16.5% during the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after purchasing an additional 5,326 shares in the last quarter. Hedge funds and other institutional investors own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.